198 related articles for article (PubMed ID: 27688833)
1. Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States.
Bilir SP; Ma Q; Zhao Z; Wehler E; Munakata J; Barber B
Am Health Drug Benefits; 2016 Jun; 9(4):203-13. PubMed ID: 27688833
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of toxicities associated with treating metastatic melanoma in eight countries.
Wehler E; Zhao Z; Pinar Bilir S; Munakata J; Barber B
Eur J Health Econ; 2017 Jan; 18(1):49-58. PubMed ID: 26721505
[TBL] [Abstract][Full Text] [Related]
3. Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review.
Copley-Merriman C; Stevinson K; Liu FX; Wang J; Mauskopf J; Zimovetz EA; Chmielowski B
Medicine (Baltimore); 2018 Aug; 97(31):e11736. PubMed ID: 30075584
[TBL] [Abstract][Full Text] [Related]
4. Economic burden associated with adverse events in patients with metastatic melanoma.
Arondekar B; Curkendall S; Monberg M; Mirakhur B; Oglesby AK; Lenhart GM; Meyer N
J Manag Care Spec Pharm; 2015 Feb; 21(2):158-64. PubMed ID: 25615005
[TBL] [Abstract][Full Text] [Related]
5. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
[TBL] [Abstract][Full Text] [Related]
6. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
7. Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly.
Ghate SR; Li Z; Tang J; Nakasato AR
Am Health Drug Benefits; 2018 Oct; 11(7):334-343. PubMed ID: 30647822
[TBL] [Abstract][Full Text] [Related]
8. Adverse event costs associated with first-line therapy for advanced non-small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors.
Stenehjem D; Lubinga SJ; Wu A; Betts KA
J Manag Care Spec Pharm; 2023 Sep; 29(9):1054-1064. PubMed ID: 37610116
[No Abstract] [Full Text] [Related]
9. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting.
Toy EL; Vekeman F; Lewis MC; Oglesby AK; Duh MS
Curr Med Res Opin; 2015 Aug; 31(8):1561-72. PubMed ID: 26086578
[TBL] [Abstract][Full Text] [Related]
10. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
Daud A; Gill J; Kamra S; Chen L; Ahuja A
J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
[TBL] [Abstract][Full Text] [Related]
11. Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies.
Burudpakdee C; Zhao Z; Munakata J; Gao S; Trochlil K; Barber B
J Med Econ; 2012; 15(2):371-7. PubMed ID: 22181051
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
[TBL] [Abstract][Full Text] [Related]
13. BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis.
Garutti M; Bergnach M; Polesel J; Palmero L; Pizzichetta MA; Puglisi F
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612138
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
George S; Bell EJ; Zheng Y; Kim R; White J; Devgan G; Smith J; Lal LS; Engel-Nitz NM; Liu FX
Oncologist; 2021 Jul; 26(7):e1205-e1215. PubMed ID: 33955118
[TBL] [Abstract][Full Text] [Related]
15. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
16. Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis.
Hong L; Huang P; Zheng X; Ye X; Zhao H; Wang J; Shao Y
Front Oncol; 2022; 12():865656. PubMed ID: 35530323
[TBL] [Abstract][Full Text] [Related]
17. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
Hagiwara M; Hackshaw MD; Oster G
J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
19. Adverse events and costs among non-metastatic castration-resistant prostate cancer patients.
Appukkuttan S; Yao J; Partridge J; Kong SX; Parkin J; Freedland SJ
J Med Econ; 2024; 27(1):145-152. PubMed ID: 38174553
[TBL] [Abstract][Full Text] [Related]
20. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
Hurvitz S; Guerin A; Brammer M; Guardino E; Zhou ZY; Latremouille Viau D; Wu EQ; Lalla D
Oncologist; 2014 Sep; 19(9):901-8. PubMed ID: 25085897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]